...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Transplantation Proceedings >Tacrolimus dose and blood concentration variability in kidney transplant recipients undergoing conversion from twice daily to once daily modified release tacrolimus.
【24h】

Tacrolimus dose and blood concentration variability in kidney transplant recipients undergoing conversion from twice daily to once daily modified release tacrolimus.

机译：他克莫司的剂量和血药浓度变异性从每天两次转为每天一次的他克莫司缓释肾移植受者。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

INTRODUCTION: Maintenance of the target blood levels of immunosuppressive drugs is one of the main factors determining transplant function. The aim of this study was to assess the effect of the conversion of tacrolimus from twice daily (Tc) to the prolonged release form administered once daily (Tc-pr) including the variability of blood concentrations and glomerular filtration rates in kidney transplantation patients. MATERIALS AND METHODS: This retrospective analysis evaluated 52 patients including 23 females, and 29 males with established grafts who underwent a scheduled change of treatment from Tc to Tc-pr. We examined data from six consecutive visits before and six visits after conversion. RESULTS: The average daily dose of Tc was 3.8+/-2.6 mg/24 h, whereas mean coefficient of variation (CoV) calculated from the visits before conversion was 68%. After the conversion, the mean total daily dose of Tc-pr was not significantly lower (3.2+/-1.8 mg), as was the mean CoV at six subsequent visits 57% (P=ns). Blood concentrations in both analyzed periods remained in the target range (Tc-pr 6.7+/-2.9 ng/mL versus Tc-pr 5.0+/-1.11) with a lower CoV in the case of Tc-pr compared to Tc (22% versus 44%; P<.001). There was no difference in graft function in the analyzed periods. After conversion, lower blood glucose levels were observed: 103.4+/-28.3 mg/dL versus 95+/-25.9 mg/dL (P<.03). CONCLUSIONS: The slow-release form of tacrolimus provided greater stability of drug blood concentrations compared with the standard form administered twice daily. The change of the tacrolimus treatment from Tc to Tc-pr dosing did not effect organ function but seemed to improve glycemic control.
机译：简介：维持免疫抑制药物的目标血药水平是决定移植功能的主要因素之一。这项研究的目的是评估他克莫司从每天两次（Tc）转换为每天一次给药的延长释放形式（Tc-pr）的效果，包括肾脏移植患者的血药浓度和肾小球滤过率变化。材料与方法：这项回顾性分析评估了52位患者，包括23位女性和29位男性，这些患者均已接受了从Tc到Tc-pr的定期治疗。我们检查了转换前连续六次访问和转换后六次访问的数据。结果：Tc的平均日剂量为3.8 +/- 2.6 mg / 24 h，而根据转化前的随访计算出的平均变异系数（CoV）为68％。转化后，Tc-pr的平均每日总剂量没有显着降低（3.2 +/- 1.8 mg），随后六次就诊的平均CoV也为57％（P = ns）。在两个分析期间的血药浓度均保持在目标范围内（Tc-pr 6.7 +/- 2.9 ng / mL对比Tc-pr 5.0 +/- 1.11），与Tc相比，Tc-pr的CoV较低（22％对比44％; P <.001）。在分析期间，移植物功能没有差异。转换后，观察到较低的血糖水平：103.4 +/- 28.3 mg / dL与95 +/- 25.9 mg / dL（P <.03）。结论：他克莫司的缓释形式与每天两次给药的标准形式相比，具有更高的药物血药浓度稳定性。他克莫司治疗从Tc改为Tc-pr剂量不会影响器官功能，但似乎可以改善血糖控制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号